RT Journal Article
SR Electronic
T1 Genomic epidemiology of SARS-CoV-2 in Colombia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.26.20135715
DO 10.1101/2020.06.26.20135715
A1 Laiton-Donato, Katherine
A1 Julián Villabona-Arenas, Christian
A1 Usme-Ciro, José A.
A1 Franco-Muñoz, Carlos
A1 Álvarez-Díaz, Diego A.
A1 Villabona-Arenas, Liz Stephany
A1 Echeverría-Londoño, Susy
A1 Cucunubá, Zulma M.
A1 Franco-Sierra, Nicolás D.
A1 Flórez, Astrid C.
A1 Ferro, Carolina
A1 Ajami, Nadim J.
A1 Walteros, Diana Marcela
A1 Prieto, Franklin
A1 Andrés Durán, Carlos
A1 Ospina-Martínez, Martha Lucia
A1 Mercado-Reyes, Marcela
YR 2020
UL http://medrxiv.org/content/early/2020/06/29/2020.06.26.20135715.abstract
AB Coronavirus disease 2019 (COVID-19) was first diagnosed in Colombia from a traveler arriving from Italy on February 26, 2020. To date, available data on the origins and number or introductions of SARS-CoV-2 into the country are limited. Here, we sequenced SARS-CoV-2 from 43 clinical samples and—together with another 73 genomes sequences available from the country—we investigated the emergence and the routes of importation of COVID-19 into Colombia using epidemiological, historical air travel and phylogenetic observations. Our study provided evidence of multiple introductions, mostly from Europe, with at least 12 lineages being documented. Phylogenetic findings validated the linkage of epidemiologically-linked transmission chains. Our results demonstrate the advantages of genome sequencing to complement COVID-19 outbreak investigation and underscores that human mobility and genetic data are relevant to complete epidemiological investigation and better characterize virus transmission dynamics at local scales.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Instituto Nacional de SaludAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The INS is the reference lab and health authority of the national network of laboratories. In case of a public health emergency or when scientific research in public health is required, the national law 9-1979, decrees 786-1990 and 2323-2006, authorizes the INS to use the biological material and associated epidemiological information without informed consent, including the anonymous disclosure of results. This study was performed following the ethical standards noted in the 1964 Declaration of Helsinki and its later amendments. The information used for this study comes from secondary sources of data that were anonymized and do not represent a risk to the community.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting this paper can be accessed through GISAID at https://www.gisaid.org/ here and used under a Creative Commons Attribution (CC-BY) licence